The immunogenicity and safety of DTaP interchangeable immunization among Korean children

Ga Young Kwak; Hyo Jin Kwon; Jong Hyun Kim; Hwang Min Kim; Joon Soo Park; Sang Hyuk Ma; Jun Gyou Kim; Jin Han Kang

doi:10.1016/j.vaccine.2012.04.094

The immunogenicity and safety of DTaP interchangeable immunization among Korean children

Ga Young Kwak, Hyo Jin Kwon, Jong Hyun Kim, Hwang Min Kim, Joon Soo Park, Sang Hyuk Ma, Jun Gyou Kim, Jin Han Kang

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Since the production of various vaccine formulations by different pharmaceutical companies and interruptions in vaccine supply cannot be fully regulated, problems caused by DTaP interchangeability may occur. However, the interchangeability data on the first primary series of DTaP vaccination have not been well described. In this study we investigated immunogenicity and overall safety of diphtheria, tetanus, pertussis in children who had adventitiously received an interchangeable DTaP vaccination. A total 97 of participants were enrolled (mean age, 11 months). High immunogenicity (1.8. ±. 0.4. IU/mL, 100%) was noted against diphtheria toxoid, and similar high immunogenicity (3.2. ±. 2.1. IU/mL, 100%) was noted against tetanus toxoid. Immunogenicity against pertussis antigen was significantly greater in the interchangeable vaccinated group compared to the control group, and 57% of the interchangeable vaccinated subjects achieved high levels of protective immunity (45.2. ±. 21.5. EU/mL). No serious adverse effects were noted, and most adverse effects resolved without treatment. The immunogenicity against each antigen was high in patients who were interchangeably vaccinated for DTaP. Our results provide clinical evidence affirming the non-inferiority of interchangeable vaccination when it cannot be avoided such as in limited vaccine supply situations or different prices.

Original language	English
Pages (from-to)	4644-4647
Number of pages	4
Journal	Vaccine
Volume	30
Issue number	31
DOIs	https://doi.org/10.1016/j.vaccine.2012.04.094
State	Published - 29 Jun 2012

Bibliographical note

Funding Information:
We are extremely grateful to the participants and their parents. We would also like to acknowledge the clinicians who referred their patients. This was supported by a grant from the Korea Food and Drug Administration ( 09122-vaccine assessment-422 ).

Keywords

DTaP vaccine
Immunogenicity
Interchangeability
Safety

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2012.04.094

Cite this

@article{9c770332042c4a3487d9697a069d7ae5,

title = "The immunogenicity and safety of DTaP interchangeable immunization among Korean children",

abstract = "Since the production of various vaccine formulations by different pharmaceutical companies and interruptions in vaccine supply cannot be fully regulated, problems caused by DTaP interchangeability may occur. However, the interchangeability data on the first primary series of DTaP vaccination have not been well described. In this study we investigated immunogenicity and overall safety of diphtheria, tetanus, pertussis in children who had adventitiously received an interchangeable DTaP vaccination. A total 97 of participants were enrolled (mean age, 11 months). High immunogenicity (1.8. ±. 0.4. IU/mL, 100%) was noted against diphtheria toxoid, and similar high immunogenicity (3.2. ±. 2.1. IU/mL, 100%) was noted against tetanus toxoid. Immunogenicity against pertussis antigen was significantly greater in the interchangeable vaccinated group compared to the control group, and 57% of the interchangeable vaccinated subjects achieved high levels of protective immunity (45.2. ±. 21.5. EU/mL). No serious adverse effects were noted, and most adverse effects resolved without treatment. The immunogenicity against each antigen was high in patients who were interchangeably vaccinated for DTaP. Our results provide clinical evidence affirming the non-inferiority of interchangeable vaccination when it cannot be avoided such as in limited vaccine supply situations or different prices.",

keywords = "DTaP vaccine, Immunogenicity, Interchangeability, Safety",

author = "Kwak, {Ga Young} and Kwon, {Hyo Jin} and Kim, {Jong Hyun} and Kim, {Hwang Min} and Park, {Joon Soo} and Ma, {Sang Hyuk} and Kim, {Jun Gyou} and Kang, {Jin Han}",

note = "Funding Information: We are extremely grateful to the participants and their parents. We would also like to acknowledge the clinicians who referred their patients. This was supported by a grant from the Korea Food and Drug Administration ( 09122-vaccine assessment-422 ).",

year = "2012",

month = jun,

day = "29",

doi = "10.1016/j.vaccine.2012.04.094",

language = "English",

volume = "30",

pages = "4644--4647",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "31",

}

TY - JOUR

T1 - The immunogenicity and safety of DTaP interchangeable immunization among Korean children

AU - Kwak, Ga Young

AU - Kwon, Hyo Jin

AU - Kim, Jong Hyun

AU - Kim, Hwang Min

AU - Park, Joon Soo

AU - Ma, Sang Hyuk

AU - Kim, Jun Gyou

AU - Kang, Jin Han

N1 - Funding Information: We are extremely grateful to the participants and their parents. We would also like to acknowledge the clinicians who referred their patients. This was supported by a grant from the Korea Food and Drug Administration ( 09122-vaccine assessment-422 ).

PY - 2012/6/29

Y1 - 2012/6/29

N2 - Since the production of various vaccine formulations by different pharmaceutical companies and interruptions in vaccine supply cannot be fully regulated, problems caused by DTaP interchangeability may occur. However, the interchangeability data on the first primary series of DTaP vaccination have not been well described. In this study we investigated immunogenicity and overall safety of diphtheria, tetanus, pertussis in children who had adventitiously received an interchangeable DTaP vaccination. A total 97 of participants were enrolled (mean age, 11 months). High immunogenicity (1.8. ±. 0.4. IU/mL, 100%) was noted against diphtheria toxoid, and similar high immunogenicity (3.2. ±. 2.1. IU/mL, 100%) was noted against tetanus toxoid. Immunogenicity against pertussis antigen was significantly greater in the interchangeable vaccinated group compared to the control group, and 57% of the interchangeable vaccinated subjects achieved high levels of protective immunity (45.2. ±. 21.5. EU/mL). No serious adverse effects were noted, and most adverse effects resolved without treatment. The immunogenicity against each antigen was high in patients who were interchangeably vaccinated for DTaP. Our results provide clinical evidence affirming the non-inferiority of interchangeable vaccination when it cannot be avoided such as in limited vaccine supply situations or different prices.

AB - Since the production of various vaccine formulations by different pharmaceutical companies and interruptions in vaccine supply cannot be fully regulated, problems caused by DTaP interchangeability may occur. However, the interchangeability data on the first primary series of DTaP vaccination have not been well described. In this study we investigated immunogenicity and overall safety of diphtheria, tetanus, pertussis in children who had adventitiously received an interchangeable DTaP vaccination. A total 97 of participants were enrolled (mean age, 11 months). High immunogenicity (1.8. ±. 0.4. IU/mL, 100%) was noted against diphtheria toxoid, and similar high immunogenicity (3.2. ±. 2.1. IU/mL, 100%) was noted against tetanus toxoid. Immunogenicity against pertussis antigen was significantly greater in the interchangeable vaccinated group compared to the control group, and 57% of the interchangeable vaccinated subjects achieved high levels of protective immunity (45.2. ±. 21.5. EU/mL). No serious adverse effects were noted, and most adverse effects resolved without treatment. The immunogenicity against each antigen was high in patients who were interchangeably vaccinated for DTaP. Our results provide clinical evidence affirming the non-inferiority of interchangeable vaccination when it cannot be avoided such as in limited vaccine supply situations or different prices.

KW - DTaP vaccine

KW - Immunogenicity

KW - Interchangeability

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84861990203&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.04.094

DO - 10.1016/j.vaccine.2012.04.094

M3 - Article

C2 - 22579862

AN - SCOPUS:84861990203

SN - 0264-410X

VL - 30

SP - 4644

EP - 4647

JO - Vaccine

JF - Vaccine

IS - 31

ER -

The immunogenicity and safety of DTaP interchangeable immunization among Korean children

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this